APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Alzheimer’s Therapeutic

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Alzheimer’s Therapeutic Market Outlook and Growth Opportunities 2026

Report ID 173962530422 December 2025199 pages

Choose your research edition.

Industry ResearchAlzheimer’s Therapeutic Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Alzheimer’s Therapeutic Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Alzheimer’s Therapeutic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Alzheimer’s Therapeutic Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Alzheimer’s Therapeutic Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Alzheimer’s Therapeutic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Alzheimer’s Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Alzheimer’s Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Alzheimer’s Therapeutic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Alzheimer’s Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Alzheimer’s Therapeutic market include Takeda Pharmaceutical Company Ltd, Merck & Co, F. Hoffman Le Roche, Eli Lilly, Inc, Pfizer Inc, Novartis International AG, H. Lundbeck A/S, Biotie Therapies and Axovant Sciences Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Alzheimer’s Therapeutic market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Alzheimer’s Therapeutic and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Alzheimer’s Therapeutic sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Alzheimer’s Therapeutic market size, projected growth trends, production technologies, key applications, and end-use industries.

Alzheimer’s Therapeutic Segment by Company

Takeda Pharmaceutical Company Ltd

Merck & Co

F. Hoffman Le Roche

Eli Lilly, Inc

Pfizer Inc

Novartis International AG

H. Lundbeck A/S

Biotie Therapies

Axovant Sciences Ltd

Astra Zeneca plc

Acadia Pharmaceuticals, Inc

Alzheimer’s Therapeutic Segment by Type

Rivastigmine

Galantamine Hydrobromide

Donepezil Hydrochloride

Memantine Hydrochloride

Alzheimer’s Therapeutic Segment by Application

Hospitals

Clinic

Other

Alzheimer’s Therapeutic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Alzheimer’s Therapeutic status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Alzheimer’s Therapeutic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Alzheimer’s Therapeutic significant trends, drivers, influence factors in global and regions.

6. To analyze Alzheimer’s Therapeutic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alzheimer’s Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alzheimer’s Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alzheimer’s Therapeutic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Alzheimer’s Therapeutic market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Alzheimer’s Therapeutic industry.

Chapter 3: Detailed analysis of Alzheimer’s Therapeutic manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Alzheimer’s Therapeutic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Alzheimer’s Therapeutic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Alzheimer’s Therapeutic Industry Trends Table 2. Alzheimer’s Therapeutic Industry Drivers Table 3. Alzheimer’s Therapeutic Industry Opportunities and Challenges Table 4. Alzheimer’s Therapeutic Industry Restraints Table 5. Global Alzheimer’s Therapeutic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Alzheimer’s Therapeutic Revenue Share by Company (2021-2026) Table 7. Global Alzheimer’s Therapeutic Sales Volume by Company (k units) & (2021-2026) Table 8. Global Alzheimer’s Therapeutic Sales Volume Share by Company (2021-2026) Table 9. Global Alzheimer’s Therapeutic Average Price (US$/unit) of Company (2021-2026) Table 10. Global Alzheimer’s Therapeutic Company Ranking, (2024-2026) & (USD Million) Table 11. Global Alzheimer’s Therapeutic Key Company Manufacturing Base & Headquarters Table 12. Global Alzheimer’s Therapeutic Company, Product Type & Application Table 13. Global Alzheimer’s Therapeutic Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Alzheimer’s Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Rivastigmine Table 18. Significant Companies of Galantamine Hydrobromide Table 19. Significant Companies of Donepezil Hydrochloride Table 20. Significant Companies of Memantine Hydrochloride Table 21. Global Alzheimer’s Therapeutic Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 22. Global Alzheimer’s Therapeutic Sales Volume by Type (2021-2026) & (k units) Table 23. Global Alzheimer’s Therapeutic Sales Volume by Type (2027-2032) & (k units) Table 24. Global Alzheimer’s Therapeutic Sales Volume Share by Type (2021-2026) Table 25. Global Alzheimer’s Therapeutic Sales Volume Share by Type (2027-2032) Table 26. Global Alzheimer’s Therapeutic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Alzheimer’s Therapeutic Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Alzheimer’s Therapeutic Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Alzheimer’s Therapeutic Sales Value Share by Type (2021-2026) Table 30. Global Alzheimer’s Therapeutic Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospitals Table 32. Significant Companies of Clinic Table 33. Significant Companies of Other Table 34. Global Alzheimer’s Therapeutic Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 35. Global Alzheimer’s Therapeutic Sales Volume by Application (2021-2026) & (k units) Table 36. Global Alzheimer’s Therapeutic Sales Volume by Application (2027-2032) & (k units) Table 37. Global Alzheimer’s Therapeutic Sales Volume Share by Application (2021-2026) Table 38. Global Alzheimer’s Therapeutic Sales Volume Share by Application (2027-2032) Table 39. Global Alzheimer’s Therapeutic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Alzheimer’s Therapeutic Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Alzheimer’s Therapeutic Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Alzheimer’s Therapeutic Sales Value Share by Application (2021-2026) Table 43. Global Alzheimer’s Therapeutic Sales Value Share by Application (2027-2032) Table 44. Global Alzheimer’s Therapeutic Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 45. Global Alzheimer’s Therapeutic Sales by Region (2021-2026) & (k units) Table 46. Global Alzheimer’s Therapeutic Sales Market Share by Region (2021-2026) Table 47. Global Alzheimer’s Therapeutic Sales by Region (2027-2032) & (k units) Table 48. Global Alzheimer’s Therapeutic Sales Market Share by Region (2027-2032) Table 49. Global Alzheimer’s Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Alzheimer’s Therapeutic Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Alzheimer’s Therapeutic Sales Value Share by Region (2021-2026) Table 52. Global Alzheimer’s Therapeutic Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Alzheimer’s Therapeutic Sales Value Share by Region (2027-2032) Table 54. Global Alzheimer’s Therapeutic Market Average Price (US$/unit) by Region (2021-2026) Table 55. Global Alzheimer’s Therapeutic Market Average Price (US$/unit) by Region (2027-2032) Table 56. Global Alzheimer’s Therapeutic Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 57. Global Alzheimer’s Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Alzheimer’s Therapeutic Sales by Country (2021-2026) & (k units) Table 59. Global Alzheimer’s Therapeutic Sales Market Share by Country (2021-2026) Table 60. Global Alzheimer’s Therapeutic Sales by Country (2027-2032) & (k units) Table 61. Global Alzheimer’s Therapeutic Sales Market Share by Country (2027-2032) Table 62. Global Alzheimer’s Therapeutic Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Alzheimer’s Therapeutic Sales Value Market Share by Country (2021-2026) Table 64. Global Alzheimer’s Therapeutic Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Alzheimer’s Therapeutic Sales Value Market Share by Country (2027-2032) Table 66. Takeda Pharmaceutical Company Ltd Company Information Table 67. Takeda Pharmaceutical Company Ltd Business Overview Table 68. Takeda Pharmaceutical Company Ltd Alzheimer’s Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 69. Takeda Pharmaceutical Company Ltd Alzheimer’s Therapeutic Product Portfolio Table 70. Takeda Pharmaceutical Company Ltd Recent Development Table 71. Merck & Co Company Information Table 72. Merck & Co Business Overview Table 73. Merck & Co Alzheimer’s Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 74. Merck & Co Alzheimer’s Therapeutic Product Portfolio Table 75. Merck & Co Recent Development Table 76. F. Hoffman Le Roche Company Information Table 77. F. Hoffman Le Roche Business Overview Table 78. F. Hoffman Le Roche Alzheimer’s Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 79. F. Hoffman Le Roche Alzheimer’s Therapeutic Product Portfolio Table 80. F. Hoffman Le Roche Recent Development Table 81. Eli Lilly, Inc Company Information Table 82. Eli Lilly, Inc Business Overview Table 83. Eli Lilly, Inc Alzheimer’s Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 84. Eli Lilly, Inc Alzheimer’s Therapeutic Product Portfolio Table 85. Eli Lilly, Inc Recent Development Table 86. Pfizer Inc Company Information Table 87. Pfizer Inc Business Overview Table 88. Pfizer Inc Alzheimer’s Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Pfizer Inc Alzheimer’s Therapeutic Product Portfolio Table 90. Pfizer Inc Recent Development Table 91. Novartis International AG Company Information Table 92. Novartis International AG Business Overview Table 93. Novartis International AG Alzheimer’s Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. Novartis International AG Alzheimer’s Therapeutic Product Portfolio Table 95. Novartis International AG Recent Development Table 96. H. Lundbeck A/S Company Information Table 97. H. Lundbeck A/S Business Overview Table 98. H. Lundbeck A/S Alzheimer’s Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. H. Lundbeck A/S Alzheimer’s Therapeutic Product Portfolio Table 100. H. Lundbeck A/S Recent Development Table 101. Biotie Therapies Company Information Table 102. Biotie Therapies Business Overview Table 103. Biotie Therapies Alzheimer’s Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Biotie Therapies Alzheimer’s Therapeutic Product Portfolio Table 105. Biotie Therapies Recent Development Table 106. Axovant Sciences Ltd Company Information Table 107. Axovant Sciences Ltd Business Overview Table 108. Axovant Sciences Ltd Alzheimer’s Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 109. Axovant Sciences Ltd Alzheimer’s Therapeutic Product Portfolio Table 110. Axovant Sciences Ltd Recent Development Table 111. Astra Zeneca plc Company Information Table 112. Astra Zeneca plc Business Overview Table 113. Astra Zeneca plc Alzheimer’s Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 114. Astra Zeneca plc Alzheimer’s Therapeutic Product Portfolio Table 115. Astra Zeneca plc Recent Development Table 116. Acadia Pharmaceuticals, Inc Company Information Table 117. Acadia Pharmaceuticals, Inc Business Overview Table 118. Acadia Pharmaceuticals, Inc Alzheimer’s Therapeutic Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 119. Acadia Pharmaceuticals, Inc Alzheimer’s Therapeutic Product Portfolio Table 120. Acadia Pharmaceuticals, Inc Recent Development Table 121. Key Raw Materials Table 122. Raw Materials Key Suppliers Table 123. Alzheimer’s Therapeutic Distributors List Table 124. Alzheimer’s Therapeutic Customers List Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Alzheimer’s Therapeutic Product Image Figure 2. Global Alzheimer’s Therapeutic Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Alzheimer’s Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 4. Global Alzheimer’s Therapeutic Sales (2021-2032) & (k units) Figure 5. Global Alzheimer’s Therapeutic Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Alzheimer’s Therapeutic Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Rivastigmine Image Figure 10. Galantamine Hydrobromide Image Figure 11. Donepezil Hydrochloride Image Figure 12. Memantine Hydrochloride Image Figure 13. Global Alzheimer’s Therapeutic Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 14. Global Alzheimer’s Therapeutic Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Alzheimer’s Therapeutic Sales Volume Share by Type (2021-2032) Figure 16. Global Alzheimer’s Therapeutic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Alzheimer’s Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Alzheimer’s Therapeutic Sales Value Share by Type (2021-2032) Figure 19. Hospitals Image Figure 20. Clinic Image Figure 21. Other Image Figure 22. Global Alzheimer’s Therapeutic Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 23. Global Alzheimer’s Therapeutic Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Alzheimer’s Therapeutic Sales Volume Share by Application (2021-2032) Figure 25. Global Alzheimer’s Therapeutic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Alzheimer’s Therapeutic Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Alzheimer’s Therapeutic Sales Value Share by Application (2021-2032) Figure 28. Global Alzheimer’s Therapeutic Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 29. Global Alzheimer’s Therapeutic Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Alzheimer’s Therapeutic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Alzheimer’s Therapeutic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Alzheimer’s Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 33. North America Alzheimer’s Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Alzheimer’s Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Alzheimer’s Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Alzheimer’s Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Alzheimer’s Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Alzheimer’s Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 39. South America Alzheimer’s Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Alzheimer’s Therapeutic Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Alzheimer’s Therapeutic Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Alzheimer’s Therapeutic Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Alzheimer’s Therapeutic Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Rivastigmine
  • Galantamine Hydrobromide
  • Donepezil Hydrochloride
  • Memantine Hydrochloride
Applications
  • Hospitals
  • Clinic
  • Other
Companies covered
  • Takeda Pharmaceutical Company Ltd
  • Merck & Co
  • F. Hoffman Le Roche
  • Eli Lilly, Inc
  • Pfizer Inc
  • Novartis International AG
  • H. Lundbeck A/S
  • Biotie Therapies
  • Axovant Sciences Ltd
  • Astra Zeneca plc
  • Acadia Pharmaceuticals, Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Alzheimer’s Therapeutic Sales Value (2021-2032)
  4. 1.2.2 Global Alzheimer’s Therapeutic Sales Volume (2021-2032)
  5. 1.2.3 Global Alzheimer’s Therapeutic Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Alzheimer’s Therapeutic Market Dynamics
  1. 2.1 Alzheimer’s Therapeutic Industry Trends
  2. 2.2 Alzheimer’s Therapeutic Industry Drivers
  3. 2.3 Alzheimer’s Therapeutic Industry Opportunities and Challenges
  4. 2.4 Alzheimer’s Therapeutic Industry Restraints
3 Alzheimer’s Therapeutic Market by Company
  1. 3.1 Global Alzheimer’s Therapeutic Company Revenue Ranking in 2025
  2. 3.2 Global Alzheimer’s Therapeutic Revenue by Company (2021-2026)
  3. 3.3 Global Alzheimer’s Therapeutic Sales Volume by Company (2021-2026)
  4. 3.4 Global Alzheimer’s Therapeutic Average Price by Company (2021-2026)
  5. 3.5 Global Alzheimer’s Therapeutic Company Ranking (2024-2026)
  6. 3.6 Global Alzheimer’s Therapeutic Company Manufacturing Base and Headquarters
  7. 3.7 Global Alzheimer’s Therapeutic Company Product Type and Application
  8. 3.8 Global Alzheimer’s Therapeutic Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Alzheimer’s Therapeutic Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Alzheimer’s Therapeutic Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Alzheimer’s Therapeutic Market by Type
  1. 4.1 Alzheimer’s Therapeutic Type Introduction
  2. 4.1.1 Rivastigmine
  3. 4.1.2 Galantamine Hydrobromide
  4. 4.1.3 Donepezil Hydrochloride
  5. 4.1.4 Memantine Hydrochloride
  6. 4.2 Global Alzheimer’s Therapeutic Sales Volume by Type
  7. 4.2.1 Global Alzheimer’s Therapeutic Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Alzheimer’s Therapeutic Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Alzheimer’s Therapeutic Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Alzheimer’s Therapeutic Sales Value by Type
  11. 4.3.1 Global Alzheimer’s Therapeutic Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Alzheimer’s Therapeutic Sales Value by Type (2021-2032)
  13. 4.3.3 Global Alzheimer’s Therapeutic Sales Value Share by Type (2021-2032)
5 Alzheimer’s Therapeutic Market by Application
  1. 5.1 Alzheimer’s Therapeutic Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Alzheimer’s Therapeutic Sales Volume by Application
  6. 5.2.1 Global Alzheimer’s Therapeutic Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Alzheimer’s Therapeutic Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Alzheimer’s Therapeutic Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Alzheimer’s Therapeutic Sales Value by Application
  10. 5.3.1 Global Alzheimer’s Therapeutic Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Alzheimer’s Therapeutic Sales Value by Application (2021-2032)
  12. 5.3.3 Global Alzheimer’s Therapeutic Sales Value Share by Application (2021-2032)
6 Alzheimer’s Therapeutic Regional Sales and Value Analysis
  1. 6.1 Global Alzheimer’s Therapeutic Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Alzheimer’s Therapeutic Sales by Region (2021-2032)
  3. 6.2.1 Global Alzheimer’s Therapeutic Sales by Region: 2021-2026
  4. 6.2.2 Global Alzheimer’s Therapeutic Sales by Region (2027-2032)
  5. 6.3 Global Alzheimer’s Therapeutic Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Alzheimer’s Therapeutic Sales Value by Region (2021-2032)
  7. 6.4.1 Global Alzheimer’s Therapeutic Sales Value by Region: 2021-2026
  8. 6.4.2 Global Alzheimer’s Therapeutic Sales Value by Region (2027-2032)
  9. 6.5 Global Alzheimer’s Therapeutic Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Alzheimer’s Therapeutic Sales Value (2021-2032)
  12. 6.6.2 North America Alzheimer’s Therapeutic Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Alzheimer’s Therapeutic Sales Value (2021-2032)
  15. 6.7.2 Europe Alzheimer’s Therapeutic Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Alzheimer’s Therapeutic Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Alzheimer’s Therapeutic Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Alzheimer’s Therapeutic Sales Value (2021-2032)
  21. 6.9.2 South America Alzheimer’s Therapeutic Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Alzheimer’s Therapeutic Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Alzheimer’s Therapeutic Sales Value Share by Country, 2025 VS 2032
7 Alzheimer’s Therapeutic Country-level Sales and Value Analysis
  1. 7.1 Global Alzheimer’s Therapeutic Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Alzheimer’s Therapeutic Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Alzheimer’s Therapeutic Sales by Country (2021-2032)
  4. 7.3.1 Global Alzheimer’s Therapeutic Sales by Country (2021-2026)
  5. 7.3.2 Global Alzheimer’s Therapeutic Sales by Country (2027-2032)
  6. 7.4 Global Alzheimer’s Therapeutic Sales Value by Country (2021-2032)
  7. 7.4.1 Global Alzheimer’s Therapeutic Sales Value by Country (2021-2026)
  8. 7.4.2 Global Alzheimer’s Therapeutic Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Alzheimer’s Therapeutic Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Alzheimer’s Therapeutic Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Alzheimer’s Therapeutic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company Ltd
  2. 8.1.1 Takeda Pharmaceutical Company Ltd Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Ltd Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Ltd Alzheimer’s Therapeutic Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Ltd Alzheimer’s Therapeutic Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Ltd Recent Developments
  7. 8.2 Merck & Co
  8. 8.2.1 Merck & Co Company Information
  9. 8.2.2 Merck & Co Business Overview
  10. 8.2.3 Merck & Co Alzheimer’s Therapeutic Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck & Co Alzheimer’s Therapeutic Product Portfolio
  12. 8.2.5 Merck & Co Recent Developments
  13. 8.3 F. Hoffman Le Roche
  14. 8.3.1 F. Hoffman Le Roche Company Information
  15. 8.3.2 F. Hoffman Le Roche Business Overview
  16. 8.3.3 F. Hoffman Le Roche Alzheimer’s Therapeutic Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 F. Hoffman Le Roche Alzheimer’s Therapeutic Product Portfolio
  18. 8.3.5 F. Hoffman Le Roche Recent Developments
  19. 8.4 Eli Lilly, Inc
  20. 8.4.1 Eli Lilly, Inc Company Information
  21. 8.4.2 Eli Lilly, Inc Business Overview
  22. 8.4.3 Eli Lilly, Inc Alzheimer’s Therapeutic Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Eli Lilly, Inc Alzheimer’s Therapeutic Product Portfolio
  24. 8.4.5 Eli Lilly, Inc Recent Developments
  25. 8.5 Pfizer Inc
  26. 8.5.1 Pfizer Inc Company Information
  27. 8.5.2 Pfizer Inc Business Overview
  28. 8.5.3 Pfizer Inc Alzheimer’s Therapeutic Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc Alzheimer’s Therapeutic Product Portfolio
  30. 8.5.5 Pfizer Inc Recent Developments
  31. 8.6 Novartis International AG
  32. 8.6.1 Novartis International AG Company Information
  33. 8.6.2 Novartis International AG Business Overview
  34. 8.6.3 Novartis International AG Alzheimer’s Therapeutic Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novartis International AG Alzheimer’s Therapeutic Product Portfolio
  36. 8.6.5 Novartis International AG Recent Developments
  37. 8.7 H. Lundbeck A/S
  38. 8.7.1 H. Lundbeck A/S Company Information
  39. 8.7.2 H. Lundbeck A/S Business Overview
  40. 8.7.3 H. Lundbeck A/S Alzheimer’s Therapeutic Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 H. Lundbeck A/S Alzheimer’s Therapeutic Product Portfolio
  42. 8.7.5 H. Lundbeck A/S Recent Developments
  43. 8.8 Biotie Therapies
  44. 8.8.1 Biotie Therapies Company Information
  45. 8.8.2 Biotie Therapies Business Overview
  46. 8.8.3 Biotie Therapies Alzheimer’s Therapeutic Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Biotie Therapies Alzheimer’s Therapeutic Product Portfolio
  48. 8.8.5 Biotie Therapies Recent Developments
  49. 8.9 Axovant Sciences Ltd
  50. 8.9.1 Axovant Sciences Ltd Company Information
  51. 8.9.2 Axovant Sciences Ltd Business Overview
  52. 8.9.3 Axovant Sciences Ltd Alzheimer’s Therapeutic Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Axovant Sciences Ltd Alzheimer’s Therapeutic Product Portfolio
  54. 8.9.5 Axovant Sciences Ltd Recent Developments
  55. 8.10 Astra Zeneca plc
  56. 8.10.1 Astra Zeneca plc Company Information
  57. 8.10.2 Astra Zeneca plc Business Overview
  58. 8.10.3 Astra Zeneca plc Alzheimer’s Therapeutic Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Astra Zeneca plc Alzheimer’s Therapeutic Product Portfolio
  60. 8.10.5 Astra Zeneca plc Recent Developments
  61. 8.11 Acadia Pharmaceuticals, Inc
  62. 8.11.1 Acadia Pharmaceuticals, Inc Company Information
  63. 8.11.2 Acadia Pharmaceuticals, Inc Business Overview
  64. 8.11.3 Acadia Pharmaceuticals, Inc Alzheimer’s Therapeutic Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Acadia Pharmaceuticals, Inc Alzheimer’s Therapeutic Product Portfolio
  66. 8.11.5 Acadia Pharmaceuticals, Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Alzheimer’s Therapeutic Value Chain Analysis
  2. 9.1.1 Alzheimer’s Therapeutic Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Alzheimer’s Therapeutic Sales Mode & Process
  6. 9.2 Alzheimer’s Therapeutic Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Alzheimer’s Therapeutic Distributors
  9. 9.2.3 Alzheimer’s Therapeutic Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst